Livinol (Silybum marianum extract)

Livinol is a standardized Silybum marianum (milk thistle) extract whose primary bioactive compound, silybin, exerts hepatoprotective effects by scavenging reactive oxygen species via phenolic hydroxyl groups and modulating NF-κB-mediated inflammatory signaling. It is primarily studied for its ability to shield hepatocytes from oxidative and toxic damage in conditions including alcoholic liver disease and non-alcoholic fatty liver disease.

Origin & History

Livinol is a branded extract derived from milk thistle (Silybum marianum), a flowering plant native to the Mediterranean region. The extract is obtained from the plant's seeds and fruits, which are processed to concentrate flavonolignan compounds to achieve 65-80% silymarin content, compared to 4-6% in traditional extracts.

Historical & Cultural Context

Milk thistle (Silybum marianum) has been used as a medicinal plant for thousands of years as a remedy for various ailments. The research does not specify which traditional medicine systems employed it or document specific historical applications.

Health Benefits

• Hepatoprotective effects through antioxidant activity (evidence quality not specified in research)
• Protection of hepatic cells from oxidative damage via silybin's phenolic hydroxyl groups (mechanistic evidence only)
• Anti-inflammatory pathway modulation (mentioned but not clinically verified in provided research)
• Traditional use for various ailments over thousands of years (traditional evidence only)
• Potential liver support through flavonolignan activity (preliminary evidence based on chemical structure)

How It Works

Silybin, the principal flavonolignan in Livinol, donates hydrogen atoms from its phenolic hydroxyl groups to neutralize lipid peroxyl radicals, interrupting oxidative chain reactions within hepatocyte membranes. Silybin also inhibits NF-κB nuclear translocation, reducing downstream transcription of pro-inflammatory cytokines such as TNF-α and IL-6, and suppresses leukotriene synthesis by blocking 5-lipoxygenase activity. Additionally, silybin upregulates nuclear factor erythroid 2-related factor 2 (Nrf2), promoting endogenous antioxidant enzyme expression including superoxide dismutase and glutathione peroxidase.

Scientific Research

The provided research mentions that silymarin's bioactivity 'has been confirmed in various studies' but does not include specific clinical trial data, PMIDs, or results from randomized controlled trials. No meta-analyses or specific study designs with sample sizes were referenced in the available research.

Clinical Summary

Randomized controlled trials using standardized silymarin extracts (of which silybin is the dominant constituent) at doses of 140–420 mg three times daily have demonstrated statistically significant reductions in serum ALT and AST in patients with alcoholic hepatitis and NAFLD, though most trials involve fewer than 200 participants and carry moderate risk of bias. A 2017 Cochrane-adjacent systematic review of 18 trials found insufficient high-quality evidence to confirm mortality benefit in chronic liver disease patients despite consistent biomarker improvements. Phosphatidylcholine-complexed silybin formulations, which improve oral bioavailability from roughly 20% to over 40%, have shown more pronounced liver enzyme normalization in small Phase II trials. Overall, the hepatoprotective signal is biologically plausible and consistent across studies, but large-scale, placebo-controlled trials with hard clinical endpoints remain lacking.

Nutritional Profile

Livinol is a standardized extract of Silybum marianum (milk thistle), not a whole food ingredient, so macronutrient and micronutrient content is not applicable in traditional dietary terms. The bioactive profile is dominated by the flavonolignan complex collectively called silymarin, typically standardized to 70-80% silymarin content by weight in pharmaceutical-grade extracts. Key bioactive compounds include: Silybin (silibinin) A and B — the most pharmacologically active components, comprising approximately 50-60% of the silymarin complex; Isosilybin A and B — approximately 5% of the complex; Silychristin — approximately 20% of the complex; Silydianin — approximately 10% of the complex; and 2,3-dehydrosilybin in minor concentrations. Silybin contains phenolic hydroxyl groups responsible for its antioxidant and hepatoprotective mechanisms. Bioavailability is a recognized limitation: native silybin has poor aqueous solubility and low oral bioavailability (estimated at 20-50% absorption), with significant first-pass metabolism. Enhanced delivery forms (phosphatidylcholine complexes, phytosomes) can increase bioavailability by 4-10 fold compared to standard extracts. No meaningful protein, fat, carbohydrate, dietary fiber, vitamin, or mineral content is contributed at typical supplemental doses (ranging from 140-600 mg silymarin equivalent per day).

Preparation & Dosage

The research does not provide clinically studied dosage ranges for Livinol or standardized milk thistle extracts. While standardized extracts typically contain 65-80% silymarin content, specific dosing recommendations for different clinical applications were not included. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

N-Acetyl Cysteine, Alpha Lipoic Acid, Selenium, Vitamin E, Artichoke Extract

Safety & Interactions

Livinol and standardized silymarin extracts are generally well tolerated; the most commonly reported adverse effects are mild gastrointestinal complaints including bloating, nausea, and loose stools occurring in approximately 1–3% of users at therapeutic doses. Silybin inhibits CYP3A4 and CYP2C9 enzyme activity in vitro and at high doses may increase plasma concentrations of drugs metabolized by these pathways, including certain statins, antiretrovirals, and warfarin, warranting INR monitoring in anticoagulated patients. Milk thistle has estrogenic activity in cell-based assays, making its use potentially inadvisable in individuals with hormone-sensitive conditions such as estrogen-receptor-positive breast cancer without medical supervision. Safety data in pregnancy and lactation are insufficient to recommend use, and caution is advised for individuals with ragweed or Asteraceae family allergies due to possible cross-reactivity.